Annuncio • Apr 22
PharmaLundensis AB to Report Q1, 2026 Results on May 21, 2026 PharmaLundensis AB announced that they will report Q1, 2026 results on May 21, 2026 Annuncio • Jan 23
PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million. PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 39,994,512
Price\Range: SEK 0.5
Transaction Features: Rights Offering Annuncio • Jan 21
PharmaLundensis AB to Report Fiscal Year 2025 Results on Feb 19, 2026 PharmaLundensis AB announced that they will report fiscal year 2025 results on Feb 19, 2026 Annuncio • Oct 22
PharmaLundensis AB to Report Q3, 2025 Results on Nov 20, 2025 PharmaLundensis AB announced that they will report Q3, 2025 results on Nov 20, 2025 Annuncio • Jul 23
PharmaLundensis AB to Report Q2, 2025 Results on Aug 21, 2025 PharmaLundensis AB announced that they will report Q2, 2025 results on Aug 21, 2025 Annuncio • Jun 10
PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million. PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 40,184,959
Price\Range: SEK 0.5
Transaction Features: Rights Offering Annuncio • Apr 02
PharmaLundensis AB to Report Q1, 2025 Results on May 01, 2025 PharmaLundensis AB announced that they will report Q1, 2025 results on May 01, 2025 Annuncio • Feb 06
PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 14.439654 million. PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 14.439654 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 14,439,654
Price\Range: SEK 1
Transaction Features: Rights Offering Annuncio • Jan 22
PharmaLundensis AB to Report Fiscal Year 2024 Results on Feb 20, 2025 PharmaLundensis AB announced that they will report fiscal year 2024 results on Feb 20, 2025 Annuncio • Oct 23
PharmaLundensis AB to Report Nine Months, 2024 Results on Nov 21, 2024 PharmaLundensis AB announced that they will report nine months, 2024 results on Nov 21, 2024 Annuncio • Jul 17
PharmaLundensis AB to Report Q2, 2024 Results on Aug 15, 2024 PharmaLundensis AB announced that they will report Q2, 2024 results on Aug 15, 2024 Annuncio • Apr 17
PharmaLundensis AB to Report Q1, 2024 Results on May 16, 2024 PharmaLundensis AB announced that they will report Q1, 2024 results on May 16, 2024 Annuncio • Jan 17
PharmaLundensis AB to Report Fiscal Year 2023 Results on Feb 15, 2024 PharmaLundensis AB announced that they will report fiscal year 2023 results on Feb 15, 2024 Annuncio • Sep 22
PharmaLundensis AB to Report Nine Months, 2023 Results on Oct 20, 2023 PharmaLundensis AB announced that they will report nine months, 2023 results on Oct 20, 2023 Recent Insider Transactions • Sep 07
Founder recently bought kr135k worth of stock On the 5th of September, Staffan Skogvall bought around 225k shares on-market at roughly kr0.60 per share. This transaction amounted to 1.1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr471k worth in shares. Annuncio • Jul 21
PharmaLundensis AB to Report Q2, 2023 Results on Aug 17, 2023 PharmaLundensis AB announced that they will report Q2, 2023 results on Aug 17, 2023 Recent Insider Transactions • Jul 04
Founder recently bought kr85k worth of stock On the 30th of June, Staffan Skogvall bought around 274k shares on-market at roughly kr0.31 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr330k worth in shares. New Risk • Jun 17
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 22% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr2.3m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr19.5m market cap, or US$1.83m). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding). Recent Insider Transactions • Mar 16
Founder recently bought kr96k worth of stock On the 13th of March, Staffan Skogvall bought around 188k shares on-market at roughly kr0.51 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr283k worth in shares. Annuncio • Jan 18
PharmaLundensis AB to Report Fiscal Year 2022 Results on Feb 16, 2023 PharmaLundensis AB announced that they will report fiscal year 2022 results on Feb 16, 2023 Board Change • Nov 16
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Founder, CEO & Director Staffan Skogvall is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Annuncio • Oct 19
PharmaLundensis AB to Report Q3, 2022 Results on Nov 17, 2022 PharmaLundensis AB announced that they will report Q3, 2022 results on Nov 17, 2022 Board Change • Apr 27
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Founder, CEO & Director Staffan Skogvall is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Annuncio • Apr 20
PharmaLundensis AB to Report Q1, 2022 Results on May 19, 2022 PharmaLundensis AB announced that they will report Q1, 2022 results on May 19, 2022 Is New 90 Day High Low • Jan 29
New 90-day low: kr0.86 The company is down 17% from its price of kr1.04 on 29 October 2020. The Swedish market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period. Is New 90 Day High Low • Dec 01
New 90-day low: kr0.94 The company is down 19% from its price of kr1.16 on 01 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period. Is New 90 Day High Low • Oct 24
New 90-day low: kr1.01 The company is down 8.0% from its price of kr1.10 on 23 July 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. Is New 90 Day High Low • Sep 23
New 90-day low: kr1.02 The company is down 15% from its price of kr1.20 on 25 June 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 16% over the same period. Annuncio • Jul 26
PharmaLundensis AB to Report Q2, 2020 Results on Aug 20, 2020 PharmaLundensis AB announced that they will report Q2, 2020 results on Aug 20, 2020 